With regard to tumor response, the ORR and DCR of a PD-1 inhibitor plus apatinib were 20.9% and 88.3%, which were better than chemotherapy alone [8, 9] or combined with anti-angiogenic agents [17]. The gene discussed is PDCD1; the disease is neoplasm.